登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05934331,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
Participants with advanced gastrointestinal tumors diagnosed histologically and/or cytologically and who have failed or are intolerant to prior standard first-line therapy (imaging confirmation required)
入选标准第 5 条
Previous immunotherapy and grade ≥3 irAE or grade ≥2 immune-related myocarditis. (for cohorts treated with combination PD-1).
排除标准第 4 条
Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
排除标准第 5 条
Participants have received Strong inhibitor/strong inducer of CYP3A4 within 14 days prior to first dose.
排除标准第 12 条
Participants who received major surgery or interventional treatment within28 days prior to the first dosing of IMP.
排除标准第 18 条
Eastern Cooperative Oncology Group (ECOG) performance status of0-1.
入选标准第 3 条
Participants with known HER2-positive gastric cancer/adenocarcinoma of the gastroesophageal junction
排除标准第 1 条
Participants with HIV infection, active HBV or HCV infection.
排除标准第 25 条
Child-bearing potential female who have positive results in pregnancy test within 7 days before the first dose or are lactating.
排除标准第 26 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05934331,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Participants who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure. Aged 18-80 years old (including boundary values) . Eastern Cooperative Oncology Group (ECOG) performance status of0-1. Life expectancy ≥ 3 months. Participants with advanced gastrointestinal tumors diagnosed histologically and/or cytologically and who have failed or are intolerant to prior standard first-line therapy (imaging confirmation required) CLDN18.2-positive subjects. At least one measurable lesion. Participants must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose. Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study.排除标准:Exclusion Criteria:
Participants with known HER2-positive gastric cancer/adenocarcinoma of the gastroesophageal junction Participants have participated in any other clinical trial within 28 days prior to 1st dosing of investigational medicinal product (IMP). Participants with anti-tumor treatment within 21 days prior to 1st dosing of IMP. Previous immunotherapy and grade ≥3 irAE or grade ≥2 immune-related myocarditis. (for cohorts treated with combination PD-1). Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0. Present peripheral sensory or motor neuropathy ≥ grade 2. Participants with uncontrolled pain. Participants with symptomatic/active central nervous system(CNS)metastases. Participants who have uncontrollable third space effusion. Participants with known hypersensitivity to antibody therapy. Participants have treated with the same target. Participants have received Strong inhibitor/strong inducer of CYP3A4 within 14 days prior to first dose. Use of any live vaccines within 28 days prior to 1st dosing of IMP. Participants with current or previous interstitial lung diseases or pneumonia requiring oral or intravenous glucocorticoids for adjuvant therapy. Participants on anticoagulants, such as heparin and vitamin K antagonists. Clinically uncontrollable persistent recurrent vomiting. Uncontrollable/severe gastrointestinal bleeding, ulceration or diarrhea within 28 days prior to first dose of IMP. Participants who received major surgery or interventional treatment within28 days prior to the first dosing of IMP. Participants who have other cancers, other than the one treated in this trial, within 2 years prior to screening. Participants who have severe cardiovascular disease. Participants who have uncontrolled or severe illness. Participants who take systemic corticosteroids (> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dosing of IMP. Participants with a known history of autoimmune diseases. Participants who have a history of immunodeficiency disease. Participants with HIV infection, active HBV or HCV infection. Child-bearing potential female who have positive results in pregnancy test within 7 days before the first dose or are lactating. Participants who have a known psychiatric diseases or disorders that may affect compliance with the trial. Participants who is judged as not eligible to participate in this study by the investigator.
引自 ClinicalTrials.gov, NCT05934331, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05934331,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。